Annex A: AVMA+ Addendum to Key Terms

This Annex provides an updated overview of key terms of the AVMA approved by the Gavi Board Board-2024-Mtg-02-Doc 11b-Annex A: AVMA Base Proposal, which themselves were updated from Board-2023-Mtg-04-Doc 10b - Annex A: AVMA Key Terms.

2026 Proposed updates are shown <u>**in bold underline**</u> and are restricted to the acceptance of EUL for vaccines against Bundibugyo virus disease (BVD), and components to be considered by the July 2026 Board, proposals known as AVMA+.

Core Terms

Design element	Details
Size	Funding requirement of US$ 750-1,000 million – with the upper end of the range set to accommodate an ambitious outcome for African products in terms of number of incentivised manufacturers and their commercial volumes
Scope	All Gavi Alliance supported vaccines (with differences in payments, see “Incentives”), fill & finish-only (i.e. drug product), and “end-to- end” drug substance + drug product.
Duration	To be <u>launched in June 2024</u> with a proposed duration of 10 years (payments can continue for a period beyond the 10-year mark, depending on tender lengths)
Eligibility	Vaccine Type: Qualifying Vaccine that is WHO Prequalified <u>**(or, in the case of a vaccine for Bundibugyo virus disease (BVD), in receipt of WHO Emergency Use Listing).**</u> Manufacturing Type: i) The Qualifying Vaccine is Fully Manufactured on the African continent; or ii) Fill & Finish of the Qualifying Vaccine is carried out in a manufacturing facility on the African continent that is Controlled by the holder of the WHO Pre- Qualification of the Qualifying Vaccine.
Procurement pathway	Via successful Gavi-UNICEF tenders and fulfil all other eligibility criteria A potential AU pooled procurement mechanism may be accommodated in the future, subject to determination in line with AVMA’s governance arrangements)

Incentives	• Milestone payment at WHO Prequalification • Per-dose accelerator payment, paid per dose, upon delivery of UNICEF tender
Priorities	Platforms: mRNA & Viral Vector ('rapid response platforms') Vaccines: • Oral Cholera Vaccine • Malaria • Measles-Rubella (MR) • Hexavalent (wP) • Yellow Fever • Pneumococcal (required profile: min. 13 valent) • Ebola (required profile: indication against 2+ Ebola species and thermostable from –20C) • Rotavirus (required profile: single-dose blow-fill-seal presentation) • Novel Tuberculosis (TB) • Maternal Respiratory Syncytial Virus (RSV) • Mpox (required profile: age 2 years, single dose regimen)
Values	**Milestone payment** • US$ 25 million: drug substance manufactured on Priority platform • US$ 20 million: drug substance for Priority vaccine • US$ 10 million: drug product for Priority vaccine ("fill and finish only") **Accelerator payment** • US$ 0.50 per dose: drug substance manufactured on Priority platform • US$ 0.50 per dose: drug substance for Priority vaccine • US$ 0.40 per dose: all other Gavi-supported drug substance US$ 0.30 per dose: for Gavi-supported drug product (i.e., "fill and finish only") up to a cap of US$ 1 per vial
Caps	• The total disbursement (Milestone and Accelerator payments) across the entire instrument is capped at: • Net funds raised for the AVMA initiative, after deducting operational costs • US$ 300 million per vaccine (pathogen) category / market • US$ 250 million for Milestone payments • US$ 250 million for "fill and finish only" • The total disbursement (Milestone and Accelerator payments) per manufacturer is capped at: • US$ 250 million, of which, US$ 50 million for "fill and finish only"

AVMA+ Addendum – H1 2026 Governance Cycle

The following addendum to the AVMA key terms applies to the programming of the additional US$ 189 million in pledges above the Board-approved US$ 1 billion ceiling, known as AVMA+.

Element	AVMA+ Addendum
Scope	Two additional windows within AVMA: (1) AVMA+ Vaccine Buy-Down Window; (2) AVMA+ Ecosystem Support Window.

Size	Up to US$ 189 million from additional pledges.
	• Vaccine Buy-down Window: balance of pledges after Ecosystem allocation.
	• Ecosystem Support Window: US$ 50 million.
	• The per-partner ceilings produced by an IRC endorsed methodology, rounded to whole millions, of:
	    ○ Africa CDC — US$ 25 million,
	    ○ WHO — US$ 20 million,
	    ○ AMA — US$ 5 million.
	• Uncommitted or undisbursed Ecosystem resources transfer to the Vaccine Buy-down Window.

Duration	Vaccine Buy-down Window: Once approved, funds deployed as African-manufactured vaccines enter the market until exhausted[1]. Ecosystem Support Window: one-off allocation for the Gavi 6.0 period. Not considered for renewal as part of the planned 2027 AVMA Course Correction (“AVMA 2.0”).
Vaccine Buy-down Window: Eligibility	African-manufactured vaccines (drug substance and/or drug product) procured through the Gavi procurement channel for Gavi-supported countries globally[1].

[1] As a discrete window to the AVMA instrument, payments under this mechanism are not counted under AVMA disbursement caps.

Vaccine Buy-down Window: Mechanism	AVMA+ funds the full Gavi-financed portion of the price[2]. Doses sit outside core country vaccine budgets, supplementing rather than drawing on the core funding envelope. For discretionary programmes (e.g. oral cholera vaccine, yellow fever preventative campaigns), AVMA+ directly funds procurement against unmet demand.
Ecosystem Support Window: Eligibility	Activities by Africa CDC, WHO, or AMA that directly mitigate risks identified in the AVMA risk framework, as approved by the Board.
Ecosystem Support Window: Disbursement	Results-based, against agreed deliverables with institutional accountability per deliverable. Managed through existing Gavi grant frameworks. Annual reporting in the AVMA Annual Report. Uncommitted resources transfer to the Vaccine Buy-down Window.
Governance	AVMA+ governed as part of the AVMA framework. Reporting through the AVMA Annual Report to the Investors Forum, PPC, and Board. Manufacturing Forum as annual review point.

[2] Where programmatic requirements justify advance payments to individual African manufacturers to secure production capacity or maintain supply continuity for Gavi-supported or AVMA-eligible vaccines, such payments would be managed under Gavi's standard risk and governance structures; with any advances subject to approval by the Gavi Market-Sensitive Decisions Committee and AFC notification.